SUBSCRIBE
SUBSCRIBE
Tristan Manalac

Tristan Manalac

Contributing Writer | News

Tristan is an independent science writer based in Metro Manila, with more than eight years of experience writing about medicine, biotech and science. Being formally trained in molecular biology, he once dreamed of collecting degrees and starting his own lab. But these days, he finds his greatest joy in a bottle of beer and a beautiful sentence. He can be reached at tristan.manalac@biospace.com, tristan@tristanmanalac.com or on LinkedIn.

Courtesy of Ken Wolter/Shutterstock
Business
Who is Nestlé Health Science and How Do They Play in Biopharma?
In the latest in Nestlé’s efforts to establish a presence in the gastroenterology space, the company will pay over $40 million upfront to Enterome as part of a new partnership.
July 18, 2022
 · 
3 min read
 · 
Tristan Manalac
Omega Therapeutics team, Courtesy Omega Therapeuti
Drug Development
Omega Gets FDA Nod to Start First-Ever Epigenomic Controller Trial
Omega Therapeutics announced Thursday that the Investigational New Drug (IND) application for its hepatocellular carcinoma (HCC) candidate OTX-2002 has been granted by the FDA.
July 15, 2022
 · 
2 min read
 · 
Tristan Manalac
MIT’s Burst-Release Microparticles Could Lead to Fewer Boosters
Once proven clinically safe and effective, MIT’s technology could pave the way toward “self-boosting” vaccines and eliminate the need for multiple shots.
July 15, 2022
 · 
2 min read
 · 
Tristan Manalac
Courtesy of Yuriko Nakao/Getty Images
Business
Theravance Finds Creative Solution to Recent Woes with $1.31B Royalty Payday
Under the terms of the deal, Theravance and Innoviva are surrendering 85% and 15% of their stakes in Trelegy in exchange for $1.1 billion and $282 million from Royalty, respectively.
July 14, 2022
 · 
2 min read
 · 
Tristan Manalac
Drug Development
Lack of Sufficient Data Sinks Atara in Mid-Phase MS Study
Atara announced that it has completed an interim analysis of its Phase II EMBOLD trial for the use of its candidate ATA188 in patients with progressive multiple sclerosis.
July 13, 2022
 · 
2 min read
 · 
Tristan Manalac
Elderly man examined by an ophthalmologist
Policy
Aldeyra Scores Late-Stage Clinical Win in Competitive Dry Eye Space
Aldeyra Therapeutics announced results from a crossover clinical trial, showing that its drug candidate reproxalap was effective in improving ocular redness and tear production in patients with dry eye disease.
July 12, 2022
 · 
3 min read
 · 
Tristan Manalac
Biotech Bay
CRISPR Pioneer Goes Small to Transform Genetic Medicine with Epigenetic Engineering
Epic Bio aims to transform genetic medicine by developing a new class of drugs that target the epigenome to alter gene expression.
July 12, 2022
 · 
3 min read
 · 
Tristan Manalac
Deals
Innoviva Snags Lucrative La Jolla Portfolio in $149M Deal
Innoviva Inc. and La Jolla Pharmaceutical Company announced Monday that they had entered into a $149-million merger agreement.
July 11, 2022
 · 
3 min read
 · 
Tristan Manalac
Drug Development
Long COVID Evidence Begins to Mount, Suggesting Biomarkers and a “Triangle” Effect
Scientists found that SARS-CoV-2 spike protein in the plasma could be a hallmark of long COVID, suggesting that the virus can linger in the body who suffer from prolonged symptoms.
July 11, 2022
 · 
4 min read
 · 
Tristan Manalac
Pascal Bachelet/BSIP/Universal Images Group via Ge
Drug Development
Adverum Slashes Workforce By 38%, Hones In On Eye Disease Candidate
Adverum Biotechnologies is cutting 78 jobs after announcing it had successfully amended its Investigational New Drug application for ADVM-022.to treat wet age-related macular degeneration.
July 8, 2022
 · 
2 min read
 · 
Tristan Manalac
Senior Female Scientist Works with High Tech Equipment in a Modern Laboratory. Her Colleagues are Working Beside Her.
Drug Development
Portage Adds Four Adenosine Candidates to Pipeline in Tarus Buyout
Portage Biotech announced Wednesday that it has inked an acquisition agreement with New York-based Tarus Therapeutics, adding four new candidates to its pipeline.
July 7, 2022
 · 
3 min read
 · 
Tristan Manalac
Drug Development
Applied Molecular Transport’s UC Candidate Proves Effective in Early-Stage Intervention
In patients stricken with ulcerative colitis for less than five years, AMT-101 was nearly three times more effective in inducing clinical remission than the placebo after eight weeks.
July 6, 2022
 · 
3 min read
 · 
Tristan Manalac
Pictured: Chinese flags in a row/iStock
Biopharma Investment in China is Thriving Amid U.S. Downturn
Many healthcare, pharmaceutical and biotech companies continue to place their bets on China, bringing fresh rounds of investments to and forging new partnerships with local firms.
July 5, 2022
 · 
3 min read
 · 
Tristan Manalac
Researchers Stumble Upon Potential Key to Slow DMD
Research scientists have found that a colony-stimulating factor 1 receptor inhibitor may also be a potential treatment for Duchenne muscular dystrophy.
July 5, 2022
 · 
2 min read
 · 
Tristan Manalac
Amarin, Secura Bio Face Disappointing Data, FDA Warning
Amarin released disappointing post hoc data from a sub-study of the REDUCE-IT trial, showing that its fish oil-derived Vascepa had little impact on serum biomarkers.
July 1, 2022
 · 
3 min read
 · 
Tristan Manalac
Load More